Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

11

Revenue 2017

AstraZeneca

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AstraZeneca's 2013 sales performance.

Astra Zeneca

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation The European Medicines Agency (EMA) has granted AstraZeneca's (AZ) COVID-19 vaccine, Vaxzevria – ChAdOx1-S [Recombinant] – full Marketing Authorisation (MA) in the EU.

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment The vaccine was well-tolerated and no safety concerns were observed. For the prevention of RSV disease in newborns and children, AstraZeneca and Sanofi’s Beyfortus (nirsevimab) was recommended for conditional

Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial Alexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) compared to an

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

AstraZeneca’s two advanced breast cancer trials meet primary endpoints Both trials showed significant improvement in progression-free survival. AstraZeneca (AZ) has announced positive high-level results from two individual advanced breast cancer trials evaluating both its next-generation oral selective

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer AstraZeneca’s Imjudo (tremelimumab) – an anti-CTLA4 antibody – in combination with Imfinzi (durvalumab) – an anti-PD-L1 antibody – has been approved by the US Food and Drug Administration (FDA) for the

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...